MATR3 promotes liver cancer progression by suppressing DHX58–mediated type I interferon response
Cancer Letters · 2024-11 · 604 · 217231
DOI: 10.1016/j.canlet.2024.217231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Zhaofeng Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China; Key Laboratory of Integrated Oncology and Intel…. Hauptthemen laut MEDLINE: Liver Neoplasms, Interferon Type I, Disease Progression, Signal Transduction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
MATR3 is a nuclear matrix protein implicated in various cancers; however, its specific role in tumor progression remains unclear. The study utilized the TCGA database to reveal that MATR3 expression is upregulated in liver cancer and is correlated with poor prognosis. Functionally, MATR3 promoted liver cancer cell proliferation and metastasis. Comprehensive RNA sequencing analysis showed that MATR3 significantly affected the type I IFN signaling pathway and DHX58 is a downstream target of MATR3. Further experiments showed that MATR3 bound to DHX58 mRNA through its RRM structural domain and recruited YTHDF2, an m6A reader, leading to degradation of DHX58 mRNA and suppression of the type I IFN signaling pathway. The knockout of MATR3 in liver cancer cells triggered a natural immune response that stimulated CD8+ T cells to eliminate liver cancer cells. This study demonstrated that MATR3 downregulates type I IFN signaling in liver cancer cells through m6A modification and inhibits immune cell infiltration within tumors. These findings expand our understanding of the role of MATR3 in liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People…
- Zhejiang University School of Medicine, Hangzhou, 310058, China.
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Hangzhou, 310006, China. Electronic address: wmmkao2@163.com.
- School of Clinical Medicine, Hangzhou Medical College, Hangzhou, 310053, China; Institute of Translational Medicine, Zhejiang University, Hangzhou, 310000, China. Electronic address: zjxu@zju.edu.cn.
Zitieren
APA
Xiao, Z., Chen, H., Xu, N., Chen, Y., Wang, S., & Xu, X. (2024). MATR3 promotes liver cancer progression by suppressing DHX58–mediated type I interferon response. Cancer Letters, 604, 217231. https://doi.org/10.1016/j.canlet.2024.217231
Vancouver
Xiao Z, Chen H, Xu N, Chen Y, Wang S, Xu X. MATR3 promotes liver cancer progression by suppressing DHX58–mediated type I interferon response. Cancer Letters. 2024;604:217231. doi:10.1016/j.canlet.2024.217231
BibTeX
@article{Xiao2024,
author = {Xiao, Zhaofeng and Chen, Huan and Xu, Nan and Chen, Yiyuan and Wang, Shuai and Xu, Xiao},
title = {MATR3 promotes liver cancer progression by suppressing DHX58–mediated type I interferon response},
journal = {Cancer Letters},
year = {2024},
volume = {604},
pages = {217231},
doi = {10.1016/j.canlet.2024.217231}
}
EUVIMED